CSIMarket
 
Aratana Therapeutics, Inc.  (PETX)
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 48
 Employees 61
 Revenues (TTM) (Millions $) 39
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Aratana Therapeutics, Inc. is a biopharmaceutical company that specializes in developing and commercializing innovative medicines for pets. The company focuses on creating drugs that can treat certain animal diseases and conditions that are currently untreatable or have a limited cure.

Aratana Therapeutics was founded in 2010 and is headquartered in Leawood, Kansas. The company has a number of drugs in its portfolio, all of which are designed to address various medical needs for dogs and cats. Some of the therapeutic areas that the company focuses on include pain management, inflammation, nausea, and regenerative medicine.

One of the key areas of focus for Aratana Therapeutics is stem cell therapy. The company has developed a line of stem cell therapies for dogs, which are designed to help regenerate and repair tissue that has been damaged due to disease or injury. These therapies have been shown to be effective in treating injuries such as joint injuries and fractures.

Another area of focus for the company is pain management. Aratana Therapeutics has developed a number of drugs that help address chronic pain in animals. These drugs have been shown to be effective in managing pain in dogs and cats, thereby improving their quality of life.

The company's portfolio also includes drugs that treat inflammation and nausea. These drugs have been developed to help animals that suffer from conditions such as chronic kidney disease and chemotherapy-induced nausea.

Aratana Therapeutics has a strong research and development team, and the company continues to invest in developing new drugs and therapies for pets. The company has partnerships with a number of veterinary clinics and research institutions, which help it to stay at the forefront of research in the animal medicine space.

Overall, Aratana Therapeutics is a leading player in the pet medicine space, and the company's innovative drugs and therapies are helping to improve the lives of dogs and cats around the world.




   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   





Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 12.48
Working Capital Ratio 18.16
Leverage Ratio (MRQ) 0.03
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.28 $
Revenues (TTM) 0.8 $
Cash Flow (TTM) -
Cash 0.77 $
Book Value 1.99 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 634,902
Net Income per Employee (TTM) -212,475
Receivable Turnover Ratio (TTM) 5.26
Inventory Turnover Ratio (TTM) 0.61
Asset Turnover Ratio (TTM) 0.32

Profitability Ratios Current
Gross Margin (MRQ) 79.36 %
Operating Margin (MRQ) -94.59 %
Net Margin (MRQ) -92.21 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.